based on a preclinical study demonstrating the synergistic antitumor effect of recombinant interleukin 2 ( ril-2 ) and beta-interferon ( ifn-beta ) on mouse tumors and previous results of a phase i study of ril-2 , a phase i study of combination therapy with human ril-2 and ifn-beta was conducted in 26 patients with advanced malignancy .
C0086418
human
C0021756
ril-2